These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 21148531)

  • 1. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety.
    Madhi SA; Maskew M; Koen A; Kuwanda L; Besselaar TG; Naidoo D; Cohen C; Valette M; Cutland CL; Sanne I
    Clin Infect Dis; 2011 Jan; 52(1):128-37. PubMed ID: 21148531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial.
    Madhi SA; Dittmer S; Kuwanda L; Venter M; Cassim H; Lazarus E; Thomas T; Liberty A; Treurnich F; Cutland CL; Weinberg A; Violari A
    AIDS; 2013 Jan; 27(3):369-79. PubMed ID: 23032417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007.
    Skowronski DM; De Serres G; Dickinson J; Petric M; Mak A; Fonseca K; Kwindt TL; Chan T; Bastien N; Charest H; Li Y
    J Infect Dis; 2009 Jan; 199(2):168-79. PubMed ID: 19086914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective, randomized, placebo-controlled trial.
    Beran J; Vesikari T; Wertzova V; Karvonen A; Honegr K; Lindblad N; Van Belle P; Peeters M; Innis BL; Devaster JM
    J Infect Dis; 2009 Dec; 200(12):1861-9. PubMed ID: 19909082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.
    Fleming DM; Crovari P; Wahn U; Klemola T; Schlesinger Y; Langussis A; Øymar K; Garcia ML; Krygier A; Costa H; Heininger U; Pregaldien JL; Cheng SM; Skinner J; Razmpour A; Saville M; Gruber WC; Forrest B;
    Pediatr Infect Dis J; 2006 Oct; 25(10):860-9. PubMed ID: 17006278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age.
    Baxter R; Patriarca PA; Ensor K; Izikson R; Goldenthal KL; Cox MM
    Vaccine; 2011 Mar; 29(12):2272-8. PubMed ID: 21277410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults.
    Leroux-Roels I; Vets E; Freese R; Seiberling M; Weber F; Salamand C; Leroux-Roels G
    Vaccine; 2008 Dec; 26(51):6614-9. PubMed ID: 18930093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose intradermal versus intramuscular trivalent inactivated seasonal influenza vaccine in lung transplant recipients.
    Manuel O; Humar A; Berutto C; Ely L; Giulieri S; Lien D; Meylan PR; Weinkauf J; Pascual M; Nador R; Aubert JD; Kumar D
    J Heart Lung Transplant; 2011 Jun; 30(6):679-84. PubMed ID: 21377898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age.
    Vesikari T; Block SL; Guerra F; Lattanzi M; Holmes S; Izu A; Gaitatzis N; Hilbert AK; Groth N
    Pediatr Infect Dis J; 2012 May; 31(5):494-500. PubMed ID: 22301476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy.
    Tanzi E; Esposito S; Bojanin J; Amendola A; Trabattoni D; Pariani E; Pinzani R; Zanetti A; Principi N
    J Med Virol; 2006 Apr; 78(4):440-5. PubMed ID: 16482542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a trivalent single dose seasonal influenza vaccine containing pandemic A(H1N1) antigen in younger and elderly subjects: a phase III open-label single-arm study.
    Loebermann M; Anders G; Brestrich G; Fritzsche C; Klammt S; Boršo D; Frimmel S; Riebold D; Reisinger EC
    Vaccine; 2011 Feb; 29(6):1228-34. PubMed ID: 21167116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, tolerability, and immunogenicity of inactivated trivalent seasonal influenza vaccine administered with a needle-free disposable-syringe jet injector.
    Simon JK; Carter M; Pasetti MF; Sztein MB; Kotloff KL; Weniger BG; Campbell JD; Levine MM
    Vaccine; 2011 Nov; 29(51):9544-50. PubMed ID: 21986218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity.
    Reisinger KS; Block SL; Izu A; Groth N; Holmes SJ
    J Infect Dis; 2009 Sep; 200(6):849-57. PubMed ID: 19673652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and sustainability of the immune response in Brazilian HIV-1-infected individuals vaccinated with inactivated triple influenza vaccine.
    Souza TM; Santini-Oliveira M; Martorelli A; Luz PM; Vasconcellos MT; Giacoia-Gripp CB; Morgado M; Nunes EP; Lemos AS; Ferreira AC; Moreira RI; Veloso VG; Siqueira M; Grinsztejn B; Camacho LA
    J Med Virol; 2016 Mar; 88(3):426-36. PubMed ID: 26267817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients.
    Tremblay CL; Rouleau D; Fortin C; Toma E; Sylla M; Cyr L; Cote S; Baz M; Sampalis J; Trautman L; Sékaly RP; Boivin G
    Vaccine; 2011 Feb; 29(7):1359-63. PubMed ID: 21185423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short communication: immunogenicity of an inactivated influenza vaccine and postvaccination influenza surveillance in HIV-infected and noninfected children and adolescents.
    Machado AA; Machado CM; Boas LS; Lopes MC; Gouvêa Ade F; Succi RC; Mendoza TR; Kanashiro TM; Machado DM
    AIDS Res Hum Retroviruses; 2011 Sep; 27(9):999-1003. PubMed ID: 21284525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective, randomized, open-label trial comparing the safety and efficacy of trivalent live attenuated and inactivated influenza vaccines in adults 60 years of age and older.
    Forrest BD; Steele AD; Hiemstra L; Rappaport R; Ambrose CS; Gruber WC
    Vaccine; 2011 May; 29(20):3633-9. PubMed ID: 21440036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults.
    Block SL; Yi T; Sheldon E; Dubovsky F; Falloon J
    Vaccine; 2011 Nov; 29(50):9391-7. PubMed ID: 21983154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study.
    Englund JA; Walter E; Black S; Blatter M; Nyberg J; Ruben FL; Decker MD;
    Pediatr Infect Dis J; 2010 Feb; 29(2):105-10. PubMed ID: 19934787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy of inactivated and live attenuated influenza vaccines.
    Monto AS; Ohmit SE; Petrie JG; Johnson E; Truscon R; Teich E; Rotthoff J; Boulton M; Victor JC
    N Engl J Med; 2009 Sep; 361(13):1260-7. PubMed ID: 19776407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.